Takei-Masuda Naomi, Iida Maiko, Ohyama Makoto, Kaneda Kaori, Ueda Kenji, Tabata Yuji
Meiji Seika Pharma Co. Ltd, Chuo-ku, Tokyo, Japan.
College of Bioresource Sciences, Nihon University, Kanagawa, Japan.
J Antibiot (Tokyo). 2025 Jan;78(1):45-53. doi: 10.1038/s41429-024-00789-1. Epub 2024 Nov 14.
Onychomycosis is a prevalent disease in many areas of the world, affecting approximately 5.5% of the global population. Among several subtypes of onychomycosis, distal-lateral-subungual onychomycosis is the most common, and topical onychomycosis agents effective against this pathogenesis require properties such as high nail penetration and low affinity for keratin, the main component of the nail. To develop novel and highly effective antifungal agents with such properties, we first established an efficient ex vivo evaluation method using bovine hoof slices and human nails, and then used this method to screen an in-house compound library. Using this strategy, we identified 1, a structure with a phenyl-pyrazole skeleton. In subsequent analyses, we investigated the structure-activity relationship of 1, permitting the identification of 28 (Development Code ME1111).
甲癣是世界上许多地区的一种常见疾病,影响着全球约5.5%的人口。在甲癣的几种亚型中,远端侧位甲下型甲癣最为常见,针对这种发病机制有效的局部用甲癣治疗药物需要具备如高指甲渗透率和对指甲主要成分角蛋白的低亲和力等特性。为了开发具有此类特性的新型高效抗真菌药物,我们首先建立了一种使用牛蹄切片和人类指甲的高效体外评估方法,然后用该方法筛选内部化合物库。通过这种策略,我们鉴定出了1,一种具有苯基吡唑骨架的结构。在后续分析中,我们研究了1的构效关系,从而鉴定出了28种(研发代码ME1111)。